Pharmacological studies on 6-amidino-2-naphthyl[4-(4,5-dihydro-1H-imidazol-2-yl)amino] benzoate dimethane sulfonate (FUT-187). I: Inhibitory activities on various kinds of enzymes in vitro and anticomplement activity in vivo.
FUT-187, a newly synthesized compound, was studied on its inhibitory activities mainly on proteolytic enzymes, in comparison with those of FUT-175 and FOY-305, known serine protease inhibitors. FUT-187, as well as FUT-175 and FOY-305, had selective inhibitory activities on serine proteases including Clr, Cls, kallikrein, trypsin, plasmin and thrombin; its activities on these enzymes except Clr and pancreatic kallikrein were relatively lower than those of FUT-175 and FOY-305. Further studies were conducted focusing on complement-mediated reactions. In spite of its lower activities against Clr and Cls, inhibitions by FUT-187 on the complement-mediated hemolysis in vitro and in vivo were only a little weaker than or equivalent to that of FUT-175. FOY-305 was ineffective in these tests. Forssman shock in guinea pigs is known to be initiated by the activation of the complement system. The protective effect of intravenous or oral FUT-187 against this shock was definitely superior to that of FUT-175. Furthermore, FUT-187 inhibited changes accompanied with Forssman shock, such as increase in lung weight, the decrease in platelet counts and CH50, and histopathological changes. These results suggested that FUT-187 should be a more potent oral therapeutic agent than FUT-175 for various inflammatory diseases attributed to the excessive activation of the complement system followed by platelet aggregation.
Research Laboratories, Torii & Co. Ltd., Ichikawa, Japan.
M
M
Oda
Y
Y
Ino
K
K
Nakamura
S
S
Kuramoto
K
K
Shimamura
M
M
Iwaki
S
S
Fujii
D000681:Amylases / Q000037:antagonists & inhibitors; D000818:Animals; D002918:Chymotrypsin / Q000037:antagonists & inhibitors; D003169:Complement Inactivator Proteins; D003171:Complement Pathway, Classical / Q000187:drug effects; D004952:Esters; D005341:Fibrinolysin / Q000037:antagonists & inhibitors; D005577:Forssman Antigen / Q000276:immunology; D016670:Gabexate / Q000031:analogs & derivatives*; D006146:Guanidines / Q000494:pharmacology; D006168:Guinea Pigs; D006821:Hyaluronoglucosaminidase / Q000037:antagonists & inhibitors; D007093:Imidazoles / Q000493:pharmacokinetics / Q000494:pharmacology*; D008049:Lipase / Q000037:antagonists & inhibitors; D008297:Male; D010741:Phospholipases A / Q000037:antagonists & inhibitors; D011480:Protease Inhibitors; D012697:Serine Endopeptidases / Q000097:blood; D014361:Trypsin Inhibitors
D003169:Complement Inactivator Proteins; D004952:Esters; D006146:Guanidines; D007093:Imidazoles; D011480:Protease Inhibitors; D014361:Trypsin Inhibitors; C034532:camostat; C058875:sepimostate mesilate; D016670:Gabexate; D005577:Forssman Antigen; D008049:Lipase; D010741:Phospholipases A; D000681:Amylases; D006821:Hyaluronoglucosaminidase; D012697:Serine Endopeptidases; D002918:Chymotrypsin; D005341:Fibrinolysin